Drug Type Small molecule drug |
Synonyms 4-O-((8R)-2-amino-8-O-(4-amino-4-deoxy-α-D-glucopyranosyl)-2,3,7-trideoxy-7-(methylamino)-D-glycero-α-D-allo-octodialdo-1,5:8,4-dipyranos-1-yl)-2-deoxy-D-streptamine, 4-O-(3α-amino-6α-((4-amino-4-deoxy-α-D-glucopyranosyl)oxy)-2,3,4,5aβ,6,7,8,8aα-octahydro-8β-hydroxy-7β-(methylamino)pyrano(3,2-b)pyran-2α-yl)-2-deoxy-D-streptamine, Apramycin (USAN/INN) + [2] |
Target |
Mechanism 30S subunit inhibitors(30S ribosomal subunit inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Molecular FormulaC21H41N5O11 |
InChIKeyXZNUGFQTQHRASN-XQENGBIVSA-N |
CAS Registry37321-09-8 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Gram-Negative Bacterial Infections | Phase 1 | DE | 02 Sep 2019 | |
Neoplasms | Preclinical | FR | - |